Mdxhealth S.A. ( (MDXH) ) has released its Q2 earnings. Here is a breakdown of the information Mdxhealth S.A. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mdxhealth S.A. is a precision diagnostics company specializing in molecular information for personalized patient diagnosis and treatment, particularly in urologic cancers and diseases. The company operates in the healthcare sector with headquarters in Irvine, California, and Herstal, Belgium.
In its latest earnings report, Mdxhealth announced a 20% year-over-year increase in second-quarter revenues, reaching $26.6 million, and achieved a positive adjusted EBITDA of $1.4 million. Additionally, the company revealed its strategic acquisition of Exosome Diagnostics from Bio-Techne, a move expected to enhance its diagnostic capabilities and accelerate revenue growth.
Key financial highlights include a 32% increase in gross profit to $17.6 million and a significant reduction in operating loss by 74% to $1.9 million. The acquisition of Exosome Diagnostics for $15 million in cash and stock is anticipated to contribute over $20 million in revenue by 2026 and enhance the company’s growth rate to approximately 30%.
The acquisition is expected to close in September, with Mdxhealth projecting it will be accretive to adjusted EBITDA by the fourth quarter of 2025. The company maintains its revenue guidance for 2025 at $108-110 million, reflecting confidence in its strategic direction and market position.
Looking ahead, Mdxhealth’s management remains optimistic about the company’s growth trajectory, driven by continued demand for its diagnostic tests and the integration of new capabilities from the Exosome Diagnostics acquisition.